title: [Chemotherapy for human gastric cancer: a review].
abstract: The authors review the actual position of medical treatment for human gastric cancer. Chemotherapy has been evaluated first in palliative situation, then as adjuvant post-surgical approach either through systemic or intraperitoneal route. Now chemotherapy may also be proposed as neoadjuvant (before surgery) treatment as part of an integrated global pluridisciplinary approach. New hopes to improve the prognosis come then from both neoadjuvant and adjuvant chemotherapy (+/- radiotherapy) and further from less toxic infusional therapies (chronomodulation), new schedules with proved active molecules (docetaxel, oxaliplatin, irinotecan, pemetrexed) as well as from new targeted treatments (against ie, EGF-receptor and angiogenesis).
authors.affiliation: Service d'Oncologie Médicale et Gastroentérologie, CHC Clinique Saint-Joseph, Liège, Belgique.
authors.forename: G
authors.initials: G
authors.lastname: Demolin
authors.forename: C
authors.initials: C
authors.lastname: Focan
authors.forename: O
authors.initials: O
authors.lastname: Plomteux
authors.forename: F
authors.initials: F
authors.lastname: Kreutz
authors.forename: N
authors.initials: N
authors.lastname: Moeneclaey
authors.forename: D
authors.initials: D
authors.lastname: Focan-Henrard
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D020360:Neoadjuvant Therapy; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy